LATEST NEWS
August 23rd, 2022
PEP-Therapy welcomes Ursula Vogel to its Board of Directors
+ READ MORE
October 5th, 2021
PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors.
+ READ MORE
July 19th, 2021
PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate, PEP-010.
+ READ MORE